[ad_1]
Advisor Partners LLC boosted its stake in Becton Dickinson and Co (NYSE:BDX) by 32.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,873 shares of the medical instruments supplier’s stock after purchasing an additional 1,191 shares during the quarter. Advisor Partners LLC’s holdings in Becton Dickinson and were worth $1,143,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the stock. Koch Industries Inc. raised its stake in Becton Dickinson and by 45,268.7% during the second quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock worth $1,391,000 after acquiring an additional 1,395,182 shares in the last quarter. Vanguard Group Inc. raised its stake in Becton Dickinson and by 8.5% during the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after acquiring an additional 1,353,780 shares in the last quarter. Winslow Capital Management LLC acquired a new position in Becton Dickinson and during the second quarter worth about $225,164,000. Janus Henderson Group PLC grew its holdings in shares of Becton Dickinson and by 1,265.9% during the second quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock worth $236,245,000 after purchasing an additional 1,122,191 shares during the last quarter. Finally, Parametric Portfolio Associates LLC grew its holdings in shares of Becton Dickinson and by 216.2% during the second quarter. Parametric Portfolio Associates LLC now owns 1,320,259 shares of the medical instruments supplier’s stock worth $257,596,000 after purchasing an additional 902,761 shares during the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.
Shares of Becton Dickinson and Co (NYSE BDX) opened at $217.14 on Friday. The company has a market capitalization of $57,811.79, a price-to-earnings ratio of 22.52, a P/E/G ratio of 1.49 and a beta of 1.12. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.54 and a quick ratio of 5.03. Becton Dickinson and Co has a 12-month low of $175.66 and a 12-month high of $248.39.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.41 by $0.07. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.33 EPS. equities analysts anticipate that Becton Dickinson and Co will post 10.95 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be paid a $0.75 dividend. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a yield of 1.38%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 229.01%.
Several analysts have recently weighed in on BDX shares. Royal Bank of Canada restated a “hold” rating and set a $210.00 price target on shares of Becton Dickinson and in a report on Wednesday, October 25th. Zacks Investment Research cut Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Deutsche Bank set a $260.00 target price on Becton Dickinson and and gave the company a “buy” rating in a report on Friday, December 29th. KeyCorp initiated coverage on Becton Dickinson and in a report on Friday, January 5th. They issued an “overweight” rating and a $260.00 target price on the stock. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a report on Friday, November 3rd. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $237.27.
TRADEMARK VIOLATION WARNING: This story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://ledgergazette.com/2018/02/11/advisor-partners-llc-raises-stake-in-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Becton Dickinson and and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link
